Biotech Values

[DewDiligence]

Epirus and Ranbaxy ink commercialization deal for Remicade FoB:

http://www.financialpost.com/markets/news/EPIRUS+Ranbaxy+Announce+Signing+BOW015+Licensing+Partnership+Broad+Range/9362660/story.html

EPIRUS Switzerland GmbH, a wholly-owned subsidiary of Boston-based EPIRUS Biopharmaceuticals, Inc., and Ranbaxy Laboratories Limited, a division of Daiichi Sankyo Company, today announced the signing of a licensing agreement for BOW015, a biosimilar infliximab, for the broad range of territories including India, selected South East Asian markets, North Africa and several other markets.

...EPIRUS and Ranbaxy will initially pursue the commercialization of BOW015...in India. EPIRUS recently announced successful Phase 3 data for BOW015 [#msg-91507828] and, in November, filed for market approval.

Subsequent to launch in India, Ranbaxy will pursue registration and commercialization of BOW015 in other territories in South East Asia, North Africa and selected other markets.

In exchange for the rights to BOW015 in the territories, EPIRUS will receive upfront, milestone, and royalty payments over the term of the agreement.